Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Axogen, Inc. - Common Stock (NQ:AXGN)

38.02 +0.63 (+1.68%)
Delayed Quote Updated: 10:10 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Axogen, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
From Axogen, Inc.
Via GlobeNewswire
News headline image
Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
News Provided by Biotech Insider on behalf of Conexeu Sciences Inc. 
From Biotech Insider
Via GlobeNewswire
News headline image
Axogen, Inc. Reports Second Quarter 2026 Financial Results
Raises Full Year Revenue Guidance to at Least 24% Growth or $279 million 
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
From Axogen, Inc.
Via GlobeNewswire
News headline image
The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
From Energy Metal News
Via GlobeNewswire
News headline image
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. Reports First Quarter 2026 Financial Results
Raises Full Year Revenue Guidance to at Least 20% Growth or $270 million 
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Announces Proposed Public Offering of Common Stock
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. Reports Third Quarter 2025 Financial Results
Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million 
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN
From DJS Law Group
Via Business Wire
News headline image
AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
From Axogen, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.